BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

Bullboard Posts

Post by hellenmon May 20, 2020 9:40am

53 Views

Post# 31050696

Tightly held ask range now to $1.87

Ask Price	Ask Size	Ask Broker
0.39	1,500	Anonymous
0.4	5,000	Anonymous
0.45	2,000	RBC Capital Markets
0.5	10,000	Anonymous
0.5	2,500	TD Securities Inc.
0.6	5,000	Anonymous
1	10,000	Anonymous
1.84	7,500	BMO Nesbitt Burns Inc.
1.87	23,500	BMO Nesbitt Burns Inc.